US STOCK
BBIO Stock Analysis
US stocks · market data · technical indicators
BridgeBio Pharma, Inc.
BBIOUS stocksQuote delayed 15 min
9/11 下午06:56 updated
$72.50
-3.58-4.71%
Open
$75.27
High
$75.50
Low
$72.12
Volume
306.39萬
BBIO price history
-13.53%Open
83.84
Latest
72.50
High
83.95
Low
72.50
Average
78.84
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score35
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
HoldCurrent Price$72.5
Target Price$61.625
Change %-4.71%
Institutional
Moderate
Foreign Ownership
Accumulating
Market Heat
Bearish
Fundamentals (US)
P/E Ratio
--
ROE
--
P/B Ratio
-5.63x
Dividend Yield
--
Market Insight
The score sits in neutral territory (35/100). Waiting for a clearer signal may be warranted. Notable price movement today (-4.71%), indicating increased market attention.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
BBIO - BridgeBio Pharma, Inc.
EPS
-3.39USD
Forward EPS
0.03USD
P/E
--
Forward P/E
2,639.24x
P/B
-5.63x
ROE
--
ROA
-26.00%
Operating margin
-43.94%
Profit margin
-97.03%
Revenue growth
120.40%
Earnings growth
--
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $243.68M | $194.51M | $154.18M | $120.70M | $110.56M |
| Gross profit | $228.63M | $184.58M | $146.07M | $114.14M | $106.91M |
| Operating income | -$107.08M | -$105.96M | -$128.43M | -$136.36M | -$133.47M |
| Net income | -$152.22M | -$164.04M | -$192.86M | -$182.74M | -$181.90M |
| Basic EPS | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 |
| Diluted EPS | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 |
Estimates vs actuals
Next earnings
2026-10-28
EPS estimate
-0.63
Revenue estimate
$268.39M
Last surprise
-33.87%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-10-28 | -0.63 | Not reported | — |
| 2026-08-10 | -0.58 | -0.78 | -33.87% |
| 2026-05-07 | -0.62 | -0.84 | -36.22% |
| 2026-02-24 | -0.62 | -0.94 | -50.63% |
| 2025-10-29 | -0.78 | -0.72 | +7.73% |
| 2025-08-05 | -0.60 | -0.95 | -57.12% |
| 2025-04-29 | -1.00 | -0.99 | +0.87% |
| 2025-02-20 | -1.09 | -1.37 | -26.09% |
| 2024-11-12 | -0.86 | -1.08 | -25.14% |
| 2024-08-01 | -0.94 | -1.01 | -7.24% |
| 2024-05-02 | -0.30 | -0.12 | +58.52% |
| 2024-02-22 | -0.80 | -0.96 | -20.13% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $1.3B | 0.02% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $351.7M | 0.25% |
| STATE STREET CORP | 2026-06-30 | $330.4M | 0.01% |
| BlackRock Inc. | 2024-06-30 | $315.3M | 0.01% |
| CITADEL ADVISORS LLC | 2026-06-30 | $280M | 0.03% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $63.8M | 0.09% |
| Bridgewater Associates, LP | 2026-06-30 | $33.4M | 0.14% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$109.10
Target range
$80.00 – $157.00
Implied upside
50.48%
Strong buy
5
Buy
14
Hold
3
Sell
0
Strong sell
0
Advertisement